456 related articles for article (PubMed ID: 12235210)
1. DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors.
Zaika AI; Slade N; Erster SH; Sansome C; Joseph TW; Pearl M; Chalas E; Moll UM
J Exp Med; 2002 Sep; 196(6):765-80. PubMed ID: 12235210
[TBL] [Abstract][Full Text] [Related]
2. Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo.
Concin N; Becker K; Slade N; Erster S; Mueller-Holzner E; Ulmer H; Daxenbichler G; Zeimet A; Zeillinger R; Marth C; Moll UM
Cancer Res; 2004 Apr; 64(7):2449-60. PubMed ID: 15059898
[TBL] [Abstract][Full Text] [Related]
3. deltaNp73 facilitates cell immortalization and cooperates with oncogenic Ras in cellular transformation in vivo.
Petrenko O; Zaika A; Moll UM
Mol Cell Biol; 2003 Aug; 23(16):5540-55. PubMed ID: 12897129
[TBL] [Abstract][Full Text] [Related]
4. Possible oncogenic potential of DeltaNp73: a newly identified isoform of human p73.
Ishimoto O; Kawahara C; Enjo K; Obinata M; Nukiwa T; Ikawa S
Cancer Res; 2002 Feb; 62(3):636-41. PubMed ID: 11830511
[TBL] [Abstract][Full Text] [Related]
5. Spatiotemporal switch from DeltaNp73 to TAp73 isoforms during nephrogenesis: impact on differentiation gene expression.
Saifudeen Z; Diavolitsis V; Stefkova J; Dipp S; Fan H; El-Dahr SS
J Biol Chem; 2005 Jun; 280(24):23094-102. PubMed ID: 15805112
[TBL] [Abstract][Full Text] [Related]
6. Involvement of N-terminally truncated variants of p73, deltaTAp73, in head and neck squamous cell cancer: a comparison with p53 mutations.
Faridoni-Laurens L; Tourpin S; Alsafadi S; Barrois M; Temam S; Janot F; Koscielny S; Bosq J; Bénard J; Ahomadegbe JC
Cell Cycle; 2008 Jun; 7(11):1587-96. PubMed ID: 18469517
[TBL] [Abstract][Full Text] [Related]
7. TAp73 and ΔNp73 have opposing roles in 5-aza-2'-deoxycytidine-induced apoptosis in breast cancer cells.
Lai J; Yang F; Zhang W; Wang Y; Xu J; Song W; Huang G; Gu J; Guan X
Mol Cells; 2014 Aug; 37(8):605-12. PubMed ID: 25134538
[TBL] [Abstract][Full Text] [Related]
8. Negative autoregulation of p73 and p53 by DeltaNp73 in regulating differentiation and survival of human neuroblastoma cells.
Nakagawa T; Takahashi M; Ozaki T; Watanabe K; Hayashi S; Hosoda M; Todo S; Nakagawara A
Cancer Lett; 2003 Jul; 197(1-2):105-9. PubMed ID: 12880968
[TBL] [Abstract][Full Text] [Related]
9. DeltaNp73 antisense activates PUMA and induces apoptosis in neuroblastoma cells.
Simões-Wüst AP; Sigrist B; Belyanskaya L; Hopkins Donaldson S; Stahel RA; Zangemeister-Wittke U
J Neurooncol; 2005 Mar; 72(1):29-34. PubMed ID: 15803372
[TBL] [Abstract][Full Text] [Related]
10. Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo.
Concin N; Hofstetter G; Berger A; Gehmacher A; Reimer D; Watrowski R; Tong D; Schuster E; Hefler L; Heim K; Mueller-Holzner E; Marth C; Moll UM; Zeimet AG; Zeillinger R
Clin Cancer Res; 2005 Dec; 11(23):8372-83. PubMed ID: 16322298
[TBL] [Abstract][Full Text] [Related]
11. TP73, an under-appreciated player in non-Hodgkin lymphoma pathogenesis and management.
Hassan HM; Dave BJ; Singh RK
Curr Mol Med; 2014 May; 14(4):432-9. PubMed ID: 24730526
[TBL] [Abstract][Full Text] [Related]
12. Cyclooxygenase inhibitors differentially modulate p73 isoforms in neuroblastoma.
Lau LM; Wolter JK; Lau JT; Cheng LS; Smith KM; Hansford LM; Zhang L; Baruchel S; Robinson F; Irwin MS
Oncogene; 2009 May; 28(19):2024-33. PubMed ID: 19363520
[TBL] [Abstract][Full Text] [Related]
13. Overexpressed TP73 induces apoptosis in medulloblastoma.
Castellino RC; De Bortoli M; Lin LL; Skapura DG; Rajan JA; Adesina AM; Perlaky L; Irwin MS; Kim JY
BMC Cancer; 2007 Jul; 7():127. PubMed ID: 17626635
[TBL] [Abstract][Full Text] [Related]
14. DeltaTAp73 upregulation correlates with poor prognosis in human tumors: putative in vivo network involving p73 isoforms, p53, and E2F-1.
Domínguez G; García JM; Peña C; Silva J; García V; Martínez L; Maximiano C; Gómez ME; Rivera JA; García-Andrade C; Bonilla F
J Clin Oncol; 2006 Feb; 24(5):805-15. PubMed ID: 16380414
[TBL] [Abstract][Full Text] [Related]
15. p63 and p73: roles in development and tumor formation.
Moll UM; Slade N
Mol Cancer Res; 2004 Jul; 2(7):371-86. PubMed ID: 15280445
[TBL] [Abstract][Full Text] [Related]
16. Transactivation-deficient Delta TA-p73 inhibits p53 by direct competition for DNA binding: implications for tumorigenesis.
Stiewe T; Theseling CC; Pützer BM
J Biol Chem; 2002 Apr; 277(16):14177-85. PubMed ID: 11844800
[TBL] [Abstract][Full Text] [Related]
17. p53 inactivation upregulates p73 expression through E2F-1 mediated transcription.
Tophkhane C; Yang SH; Jiang Y; Ma Z; Subramaniam D; Anant S; Yogosawa S; Sakai T; Liu WG; Edgerton S; Thor A; Yang X
PLoS One; 2012; 7(8):e43564. PubMed ID: 22952705
[TBL] [Abstract][Full Text] [Related]
18. Family friction as ΔNp73 antagonises p73 and p53.
Bailey SG; Cragg MS; Townsend PA
Int J Biochem Cell Biol; 2011 Apr; 43(4):482-6. PubMed ID: 21216303
[TBL] [Abstract][Full Text] [Related]
19. TAp73/Delta Np73 influences apoptotic response, chemosensitivity and prognosis in hepatocellular carcinoma.
Müller M; Schilling T; Sayan AE; Kairat A; Lorenz K; Schulze-Bergkamen H; Oren M; Koch A; Tannapfel A; Stremmel W; Melino G; Krammer PH
Cell Death Differ; 2005 Dec; 12(12):1564-77. PubMed ID: 16195739
[TBL] [Abstract][Full Text] [Related]
20. Differential control of TAp73 and DeltaNp73 protein stability by the ring finger ubiquitin ligase PIR2.
Sayan BS; Yang AL; Conforti F; Tucci P; Piro MC; Browne GJ; Agostini M; Bernardini S; Knight RA; Mak TW; Melino G
Proc Natl Acad Sci U S A; 2010 Jul; 107(29):12877-82. PubMed ID: 20615966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
